

Bobin Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3245610/publications.pdf>

Version: 2024-02-01

31
papers

251
citations

1040056

9
h-index

1058476

14
g-index

36
all docs

36
docs citations

36
times ranked

362
citing authors

#	ARTICLE	IF	CITATIONS
1	Icaritin induces lytic cytotoxicity in extranodal NK/T-cell lymphoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 17.	8.6	32
2	Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway. <i>Investigational New Drugs</i> , 2018, 36, 571-580.	2.6	30
3	Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients. <i>BMC Ophthalmology</i> , 2020, 20, 189.	1.4	23
4	Clinical Relevance of the High Prevalence of MYD88 L265P Mutated Vitreoretinal Lymphoma Identified by Droplet Digital Polymerase Chain Reaction. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 448-455.	1.8	16
5	High Level of IL-10 in Cerebrospinal Fluid is Specific for Diagnosis of Primary Central Nervous System Lymphoma. <i>Cancer Management and Research</i> , 2020, Volume 12, 6261-6268.	1.9	16
6	Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China. <i>Cancer Communications</i> , 2021, 41, 229-239.	9.2	15
7	Resveratrol inhibits Extranodal NK/T cell lymphoma through activation of DNA damage response pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 133.	8.6	14
8	Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma. <i>Oncology Reports</i> , 2019, 41, 397-404.	2.6	11
9	The diagnostic value of IL-10 and IL-6 level in vitreous fluid and aqueous humor for vitreoretinal lymphoma. <i>Clinica Chimica Acta</i> , 2021, 515, 21-26.	1.1	10
10	Improvement of outcomes of an escalated high-dose methotrexate-based regimen for patients with newly diagnosed primary central nervous system lymphoma: a real-world cohort study. <i>Cancer Management and Research</i> , 2021, Volume 13, 6115-6122.	1.9	10
11	Effectiveness of digital PCR for MYD88L265P detection in vitreous fluid for primary central nervous system lymphoma diagnosis. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 301-308.	1.8	9
12	Myeloid/natural killer cell precursor acute leukemia with multiple subcutaneous nodules as the initial presentation: a case report and literature review. <i>International Journal of Hematology</i> , 2009, 90, 243-247.	1.6	7
13	Myeloid/NK cell acute leukemia. <i>International Journal of Hematology</i> , 2009, 89, 365-367.	1.6	6
14	Analyses on clinical characteristic and prognoses of 41 patients with chronic myelomonocytic leukemia in China. <i>Leukemia Research</i> , 2010, 34, 458-462.	0.8	6
15	Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis. <i>PLoS ONE</i> , 2015, 10, e0142422.	2.5	6
16	SLC7A5 act as a potential leukemic transformation target gene in myelodysplastic syndrome. <i>Oncotarget</i> , 2016, 7, 6566-6575.	1.8	6
17	The role of ABCB1 polymorphism as a prognostic marker for primary central nervous system lymphoma. <i>Annals of Hematology</i> , 2019, 98, 923-930.	1.8	5
18	Optical Coherence Tomography Benefits the Diagnosis and Follow-Up of Primary Central Nervous System Lymphoma with Intraocular Involvement. <i>Cancer Management and Research</i> , 2022, Volume 14, 1007-1018.	1.9	5

#	ARTICLE	IF	CITATIONS
19	Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma. <i>Oncotarget</i> , 2017, 8, 53701-53713.	1.8	4
20	Resveratrol activates DNA damage response through inhibition of polo-like kinase 1 (PLK1) in natural killer/T cell lymphoma. <i>Annals of Translational Medicine</i> , 2020, 8, 688-688.	1.7	4
21	Evaluation and Application of Population Pharmacokinetic Models for Identifying Delayed Methotrexate Elimination in Patients With Primary Central Nervous System Lymphoma. <i>Frontiers in Pharmacology</i> , 2022, 13, 817673.	3.5	4
22	Polyneuropathy as Novel Initial Manifestation in a Case of "Nonsecretory" POEMS Syndrome with Sjögren's Syndrome. <i>Case Reports in Medicine</i> , 2017, 2017, 1-6.	0.7	3
23	Elevated expression of the EZH2 gene in CALR-mutated patients with primary myelofibrosis. <i>Annals of Hematology</i> , 2018, 97, 1193-1208.	1.8	3
24	Primary laryngeal manifestation in precursor T-cell acute lymphoblastic leukemia. <i>Oncology Letters</i> , 2015, 9, 691-694.	1.8	2
25	<p>Central Nervous System Involvement in Patients with Diffuse Large B Cell Lymphoma: Analysis of the Risk Factors and Prognosis from a Single-Center Retrospective Cohort Study</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10175-10185.	1.9	2
26	Efficacy and Safety of Pemetrexed Combined with Lenalidomide in the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma. <i>Blood</i> , 2020, 136, 2-3.	1.4	2
27	Analysis on Characteristics of Dysplasia in 345 Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2008, 112, 5100-5100.	1.4	0
28	Prognostic Factors in Chronic Myelomonocytic Leukemia: A Retrospective Analysis of 41 Patients. <i>Blood</i> , 2008, 112, 4279-4279.	1.4	0
29	Atypical Chronic Myeloid Leukemia: An Analysis of 9 Cases. <i>Blood</i> , 2008, 112, 4285-4285.	1.4	0
30	The Outcome of Refractory or Relapsed but Not Refractory Diffuse Large B-Cell Lymphoma in China: Results from the Real-TREND Study. <i>Blood</i> , 2018, 132, 5913-5913.	1.4	0
31	Circulating microRNAs Is a Potential Prognostic Biomarker in Primary Central Nervous System Lymphoma. <i>Blood</i> , 2020, 136, 40-41.	1.4	0